Sat.Jul 13, 2024 - Fri.Jul 19, 2024

article thumbnail

77% of researchers not using alternatives to animal testing

Drug Discovery World

New survey findings have revealed that 77% of R&D professionals are not using in vitro cell-based alternatives to animal testing, and only 23% describe themselves as ‘very familiar’ with any kind of animal model alternative. More than 350 survey respondents participated in the survey by The Pistoia Alliance, including representatives from pharma companies, regulators, and CROs.

article thumbnail

Ant insights lead to robot navigation breakthrough

Science Daily: Pharmacology News

Have you ever wondered how insects are able to go so far beyond their home and still find their way? The answer to this question is not only relevant to biology but also to making the AI for tiny, autonomous robots. Drone-researchers felt inspired by biological findings on how ants visually recognize their environment and combine it with counting their steps in order to get safely back home.

Research 136
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Artiva prices $167M IPO, riding optimism for autoimmune cell therapy

BioPharma Drive: Drug Pricing

The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.

Therapies 131
article thumbnail

Nanoemulsion based lipid nanoparticles for effective demethylcantharidin delivery to cure liver cancer

Chemical Biology and Drug Design

Demethylcantharidin (DEM) is a widely used antitumor drug; however, its poor tumor targeting and serious organotoxicity limit its application. The aim of this study was to develop a new drug delivery system for efficient delivery of DEM. DEM, demethylcalcin; DNLNs, nanoemulsion based lipid nanoparticles containing demethylcantharidin; EPR, enhanced permeability and retention; PEG-400, polyethylene glycol 400.

Drugs 100
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

This week in drug discovery (15-19 July) 

Drug Discovery World

News round-up for 15-19 July by DDW Senior Digital Content Editor Diana Spencer. The chosen news stories this week all feature therapies that could have significant impact on the future treatment of cancer, particularly haematological malignancies, but also solid tumours. The top stories: Bacteriophage study offers new hope in treating GVHD Researchers from Japan have identified a bacteriophage-derived enzyme that holds promise for future applications in preventing or treating acute graft-versus

Drugs 130
article thumbnail

Psilocybin generates psychedelic experience by disrupting brain network

Science Daily: Pharmacology News

Researchers report that psilocybin, the active ingredient in magic mushrooms, destabilizes a critical network of brain areas involved in introspective thinking. The findings provide a neurobiological explanation for the drug's mind-bending effects.

Research 128

More Trending

article thumbnail

Investigating potential mechanisms of vitamin D against thyroid cancer via network pharmacology and experimental validation

Chemical Biology and Drug Design

This study provides preliminary elucidation of multiple pharmacological targets, biological processes and signaling pathways of VD against TC. These findings offer valuable insights for future therapeutic strategies targeting TC. Abstract Thyroid cancer (TC) is one of the most common endocrine malignancies worldwide. Increasing evidence suggests that vitamin D (VD) has potential benefits in the treatment of TC.

Treatment 100
article thumbnail

€12 million raised for extracellular protein degradation research

Drug Discovery World

Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD). TPD is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies.

article thumbnail

Waste Styrofoam can now be converted into polymers for electronics

Science Daily: Pharmacology News

A new study describes a chemical reaction that can convert Styrofoam into a high-value conducting polymer known as PEDOT:PSS. Researchers also noted that the upgraded plastic waste can be successfully incorporated into functional electronic devices, including silicon-based hybrid solar cells and organic electrochemical transistors.

Research 124
article thumbnail

German Patient is 7th Person Probably Cured of HIV

Drugs.com

FRIDAY, July 19, 2024 -- A German man has become the seventh person to apparently be cured of HIV, researchers report.The 60-year-old man, referred to as the “next Berlin Patient,” was treated with a stem cell transplant in October 2015 for acute my.

Research 116
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis

Chemical Biology and Drug Design

Several Bruton's tyrosine kinase (BTK) inhibitors have been shown in studies to be effective in the inhibition of biological activity analysis and in animal models. This review focuses on the BTK inhibition mechanism and its possible impact on immune-mediated disease, as well as the types being investigated for RA, preclinical and clinical investigations and future research opportunities.

article thumbnail

Dr Gonzalez-Aseguinolaza recognised for gene therapy research

Drug Discovery World

Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer of Vivet Therapeutics, has been awarded the Rosalind Franklin Society (RFS) Special Award in Science given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society. The award recognises Dr Gonzalez-Aseguinolaza’s remarkable contributions and dedication to advancing scientific knowledge.

Therapies 130
article thumbnail

New geological datings place the first European hominids in the south of the Iberian Peninsula 1.3 million years ago

Science Daily: Pharmacology News

One of the most important controversies about human evolution and expansion is when and by what route the first hominids arrived in Europe from the African continent. Now, geological dating techniques at the Orce sites (Baza basin, Granada, Spain) place the human remains found in this area as the oldest in Europe, at approximately 1.3 million years old.

125
125
article thumbnail

Studies Support Use of Daily Antibiotic to Prevent STDs in High-Risk Groups

Drugs.com

FRIDAY, July 19, 2024 -- It's long been known that popping the antibiotic doxycycline within 72 hours of a risky sexual encounter can greatly reduce a person's risk for a sexually transmitted infection (STI). In fact, the U.S. Centers for Disease.

Disease 116
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Leveraging binding pose metadynamics to optimise target fishing predictions for three diverse ligands and their true targets

Chemical Biology and Drug Design

The ability of binding pose metadynamics to improve the rankings of true targets predicted via pharmacophore mapping was investigated using three diverse ligands and their six true targets. Binding pose metadynamics improved the predicted rankings for four out of the six true targets, while also providing the highest-ranked predictions. Abstract Computational target fishing plays an important role in target identification, particularly in drug discovery campaigns utilizing phenotypic screening.

Drugs 100
article thumbnail

AI data sharing company Briefly Bio launches with $1.2m funding

Drug Discovery World

Briefly Bio, a software company that hopes to make lab work more reproducible by helping scientists capture and share their work, has launched with a $1.2m pre-seed funding round. The financing was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech. In preclinical research, it’s estimated that over 50% of efforts to reproduce experiments fail, costing the industry over $50bn each year.

article thumbnail

Microbes found to destroy certain 'forever chemicals'

Science Daily: Pharmacology News

An environmental engineering team has discovered that specific bacterial species can cleave the strong fluorine-to-carbon bond certain kinds of 'forever chemical' water pollutants, offering promise for low-cost treatments of contaminated drinking water.

article thumbnail

New MS Drug Kesimpta May Help Keep Symptoms at Bay

Drugs.com

THURSDAY, July 18, 2024 -- A new monoclonal antibody treatment called Kesimpta (ofatumumab) appears to improve on an older drug in pushing multiple sclerosis (MS) into remission, a new trial shows.Funded by Kesimpta's maker, Novartis, the trial.

Drugs 116
article thumbnail

Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex

BioPharma Drive: Drug Pricing

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs 113
article thumbnail

New bone marrow model ‘big news’ for drug discovery

Drug Discovery World

Scientists have created the first bioengineered bone marrow model which can support the type of human stem cells that are crucial for bone marrow transplants and in vitro study work. The research – published in Nature Communications and led by the University of Glasgow – replicates key aspects of the human bone marrow microenvironment, to enable the support of rare long-term hematopoietic stem cells, or LT-HSCs.

article thumbnail

Scientists find that small regions of the brain can take micro-naps while the rest of the brain is awake and vice versa

Science Daily: Pharmacology News

For the first time, scientists have found that sleep can be detected by patterns of neuronal activity just milliseconds long, 1000 times shorter than a second, revealing a new way to study and understand the basic brain wave patterns that govern consciousness.

article thumbnail

Fall of Roe v. Wade Has Made Access to Ob/Gyns Tougher in Many States: Report

Drugs.com

THURSDAY, July 18, 2024 -- Ever since the Supreme Court overturned Roe v. Wade in June 2022, even more women have struggled to find reproductive care, a new report warns.Issued Thursday by the Commonwealth Fund, the report shows that women living.

115
115
article thumbnail

Obesity pill from Roche shows promising weight loss in small study

BioPharma Drive: Drug Pricing

Treatment led to "clinically meaningful" weight loss over four weeks, but longer studies will be needed to compare it to Wegovy and Zepbound.

Treatment 122
article thumbnail

UK life sciences can lead the way in cannabinoid R&D, says report

Drug Discovery World

The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report suggests the UK can build on the success of GW Pharmaceuticals, whose multiple sclerosis treatment product nabiximols was the first natural cannabis plant derivative to gain market approval in any country.

Science 130
article thumbnail

New snake discovery rewrites history, points to North America's role in snake evolution

Science Daily: Pharmacology News

A new species of fossil snake unearthed in Wyoming is rewriting our understanding of snake evolution. The discovery, based on four remarkably well-preserved specimens found curled together in a burrow, reveals a new species named Hibernophis breithaupti. This snake lived in North America 34 million years ago and sheds light on the origin and diversification of boas and pythons.

118
118
article thumbnail

Science Reveals 'Magic Mushroom' Chemical's Mind-Altering Effects

Drugs.com

THURSDAY, July 18, 2024 -- “Magic” mushrooms achieve their psychedelic effects by temporarily scrambling a brain network involved in introspective thinking like daydreaming and remembering, a new study reports.Brain scans of people who took psi.

Science 115
article thumbnail

An immune factor in the brain plays critical roles in neuron function and aging

Broad Institute

An immune factor in the brain plays critical roles in neuron function and aging By Tom Ulrich July 19, 2024 Breadcrumb Home An immune factor in the brain plays critical roles in neuron function and aging Study highlights unexpected interactions between innate immune system and neurons, raises questions about additional roles for immune system in the brain with aging.

article thumbnail

CatalYm raises $150m for cancer therapy visugromab

Drug Discovery World

CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III also participated in the round.

Therapies 130
article thumbnail

Evidence for butchery of giant armadillo-like mammals in Argentina 21,000 years ago

Science Daily: Pharmacology News

Cut marks on fossils could be evidence of humans exploiting large mammals in Argentina more than 20,000 years ago, according to a new study.

134
134
article thumbnail

Irregular Sleep Could Raise Your Odds for Diabetes

Drugs.com

WEDNESDAY, July 17, 2024 (HeathDay News) -- Sleeping long hours one night but only a few hours the next can be unhealthy, with a new study finding "irregular" sleep patterns could be a risk factor for type 2 diabetes.The results "underscore the.

115
115
article thumbnail

What is the medical definition of obesity?

Antidote

Obesity, a condition that impacts 2 out of 5 adults in the United States , has become a significant health concern, both due to the impacts it has on individuals with the condition and the effect it can have on the overall medical system. It is estimated that obesity is responsible for nearly $1.73 billion in excess treatment costs annually, compounded by the fact that individuals with obesity are far more likely to have other conditions such as hypertension, diabetes, and osteoarthritis.

Treatment 111
article thumbnail

Acute myeloid leukaemia drug gets fast-tracked

Drug Discovery World

The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML). The drug is intended for patients with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukaemia (MLL) protein interaction, which plays key roles in gene expression and protein i

article thumbnail

Paleolithic diets are not without risks

Science Daily: Pharmacology News

High-protein diets, known as 'Paleolithic diets', are popular. Using mouse models, scientists have studied their impact. While effective in regulating weight and stabilizing diabetes, these diets are not without risks. Excess protein greatly increases ammonium production, overwhelming the liver. Excess ammonium can cause neurological disorders and, in severe cases, lead to coma.

article thumbnail

Ancient Viruses Might Be Spurring Modern-Day Cancers

Drugs.com

FRIDAY, July 19, 2024 -- Cancer growth can be fueled by flecks of ancient viral DNA lodged into the genetics of modern humans, a new study says.Overall, about 8% of the human genome is made of bits of DNA left behind by viruses that infected our.

Virus 111